Zobrazeno 1 - 10
of 18
pro vyhledávání: '"N. E. Uvarova"'
Publikováno v:
Регуляторные исследования и экспертиза лекарственных средств, Vol 13, Iss 4, Pp 493-502 (2023)
Scientific relevance. The development of new medicinal products to treat influenza is motivated by the limitations of existing treatment options, the emergence of drug resistance, and the health consequences of influenza epidemics associated with the
Externí odkaz:
https://doaj.org/article/04dda8df547d49b78c60ce5ca97f0368
Publikováno v:
Регуляторные исследования и экспертиза лекарственных средств, Vol 13, Iss 2-1, Pp 302-315 (2023)
In order to obtain valid results when studying the bioavailability of medicinal products containing magnesium salts, it is necessary to take into account endogenous levels of the macroelement in the body. The aim of the study was to conduct a systema
Externí odkaz:
https://doaj.org/article/05d6c2e479d34f2d82d03cb6c22603bb
Publikováno v:
Регуляторные исследования и экспертиза лекарственных средств, Vol 10, Iss 3, Pp 152-163 (2020)
No new drug can be used in clinical practice without marketing authorisation. Acquisition of the necessary amount of clinical data may take several years, which is especially critical for pernicious diseases for which no alternative therapy is availa
Externí odkaz:
https://doaj.org/article/0443be53ed234d96a1a6033af216831e
Autor:
D. V. Goryachev, N. E. Uvarova
Publikováno v:
Регуляторные исследования и экспертиза лекарственных средств, Vol 9, Iss 3, Pp 184-190 (2019)
Generic drugs are widely discussed in the scientific literature. Their key advantage is high availability in the medical practice due to the possibility of a significant reduction in developer costs. In most cases the efficacy and safety of generic o
Externí odkaz:
https://doaj.org/article/2cac9d95c7f143f394b8323b92f6604d
Autor:
D. V. Goryachev, N. E. Uvarova
Publikováno v:
Регуляторные исследования и экспертиза лекарственных средств, Vol 9, Iss 2, Pp 79-84 (2019)
The introduction of the «therapeutic equivalence» concept into the Russian legislation is critical for evaluation of medicines interchangeability and for recognising them as generics. It is stipulated by the legislation that therapeutic equivalence
Externí odkaz:
https://doaj.org/article/a9f7fa62c9ca4a2fad85856307625914
Publikováno v:
Регуляторные исследования и экспертиза лекарственных средств, Vol 8, Iss 3, Pp 151-157 (2018)
The Government of the Russian Federation approved the State strategy of combating the spread of HIV aimed at prevention of HIV epidemic. One of the goals of the Strategy is to increase the coverage of antiretroviral therapy for people infected with H
Externí odkaz:
https://doaj.org/article/0d6b92d5d53847c7a6ee89ff0a879418
Publikováno v:
Регуляторные исследования и экспертиза лекарственных средств, Vol 8, Iss 1, Pp 11-16 (2018)
Expansion of the range of new medicines leads to a significant increase in healthcare spending and, consequently, to the appearance of more affordable generic drugs. A drug can be recognised as generic if there is sufficient evidence of equivalent st
Externí odkaz:
https://doaj.org/article/afed547b53794c43907842c8f1db5bbc
Publikováno v:
Meditsinskiy sovet = Medical Council. :158-167
Introduction. In the last decade, approaches to the treatment of chronic viral hepatitis C (HCV) have undergone significant changes. The new WHO strategy aims to eliminate HCV by 2030 by reducing the number of new infections and deaths by simplifying
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13a0e3614e6fc3e7796bafa54fb57c98
https://doi.org/10.21518/ms2023-143
https://doi.org/10.21518/ms2023-143
Publikováno v:
Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation.
The development of new medicinal products to treat influenza is motivated by the limitations of existing treatment options, the emergence of drug resistance, and the health consequences of influenza epidemics associated with the highly contagious nat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::482afe997e64cd41169b19b66dd9d471
https://doi.org/10.30895/1991-2919-2022-400
https://doi.org/10.30895/1991-2919-2022-400
Publikováno v:
Pharmaceutical Chemistry Journal. 55:1-5
A bioequivalence (BE) study is one of the key stages of investigations required for the registration of oral generic drugs. The planning of this type of study is determined by many factors, including the linearity of the pharmacokinetics of the activ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34c9f1fffadd6387dc5cd2f7c68d651e
https://doi.org/10.1007/s11094-021-02361-9
https://doi.org/10.1007/s11094-021-02361-9